Trueblood Wealth Management LLC bought a new stake in shares of Boston Scientific Co. (NYSE:BSX – Free Report) during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 2,732 shares of the medical equipment provider’s stock, valued at approximately $210,000.
A number of other institutional investors and hedge funds also recently made changes to their positions in BSX. BOKF NA raised its stake in shares of Boston Scientific by 14.0% in the 2nd quarter. BOKF NA now owns 3,065 shares of the medical equipment provider’s stock valued at $236,000 after acquiring an additional 377 shares in the last quarter. Qsemble Capital Management LP bought a new position in shares of Boston Scientific in the second quarter valued at approximately $2,690,000. LPL Financial LLC raised its position in shares of Boston Scientific by 6.4% in the second quarter. LPL Financial LLC now owns 1,015,687 shares of the medical equipment provider’s stock valued at $78,218,000 after purchasing an additional 61,350 shares during the period. SP Asset Management LLC lifted its stake in shares of Boston Scientific by 7.7% in the second quarter. SP Asset Management LLC now owns 4,064 shares of the medical equipment provider’s stock worth $313,000 after buying an additional 292 shares during the last quarter. Finally, MGO One Seven LLC boosted its holdings in shares of Boston Scientific by 101.5% during the 2nd quarter. MGO One Seven LLC now owns 16,672 shares of the medical equipment provider’s stock worth $1,284,000 after buying an additional 8,399 shares during the period. Institutional investors and hedge funds own 89.07% of the company’s stock.
Insider Activity at Boston Scientific
In other news, EVP Wendy Carruthers sold 6,983 shares of the stock in a transaction on Thursday, August 1st. The stock was sold at an average price of $74.12, for a total transaction of $517,579.96. Following the sale, the executive vice president now owns 40,188 shares in the company, valued at $2,978,734.56. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Insiders sold 20,949 shares of company stock valued at $1,627,877 in the last three months. Corporate insiders own 0.50% of the company’s stock.
Analysts Set New Price Targets
View Our Latest Analysis on BSX
Boston Scientific Stock Down 0.2 %
BSX opened at $82.87 on Thursday. The firm has a market cap of $121.58 billion, a price-to-earnings ratio of 69.64, a PEG ratio of 2.71 and a beta of 0.79. The company has a debt-to-equity ratio of 0.44, a quick ratio of 1.14 and a current ratio of 1.61. The firm’s 50-day simple moving average is $77.79 and its 200-day simple moving average is $73.87. Boston Scientific Co. has a twelve month low of $48.35 and a twelve month high of $83.27.
Boston Scientific (NYSE:BSX – Get Free Report) last issued its quarterly earnings data on Wednesday, July 24th. The medical equipment provider reported $0.62 earnings per share for the quarter, topping the consensus estimate of $0.58 by $0.04. Boston Scientific had a net margin of 12.00% and a return on equity of 16.59%. The firm had revenue of $4.12 billion for the quarter, compared to analysts’ expectations of $4.02 billion. During the same period in the prior year, the firm earned $0.53 earnings per share. The company’s quarterly revenue was up 14.5% compared to the same quarter last year. Equities research analysts anticipate that Boston Scientific Co. will post 2.4 EPS for the current fiscal year.
Boston Scientific Profile
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.
Featured Stories
- Five stocks we like better than Boston Scientific
- High Dividend REITs: Are They an Ideal Way to Diversify?
- Can Roblox Really Grow to 1 Billion Active Daily Users?
- Profitably Trade Stocks at 52-Week Highs
- Biotech Breakout: Stocks for Your Watchlist
- 3 Monster Growth Stocks to Buy Now
- Dave & Buster’s Stock Isn’t Playing Around: It’s Building Value
Want to see what other hedge funds are holding BSX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Boston Scientific Co. (NYSE:BSX – Free Report).
Receive News & Ratings for Boston Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific and related companies with MarketBeat.com's FREE daily email newsletter.